Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act) : a multicentre, retrospective study

Abstract

Please read abstract in the article.

Description

DATA SHARING : The de-identified individual-level patient data, data dictionary, and protocol for this study can be provided to researchers upon written request 24–36 months after publication of the Article. Please send enquiries to the corresponding author. A detailed proposal for how the data will be used is required and we will assess applications on a case-by-case basis, and only for the purpose of individual participant data meta-analysis. A data access agreement must be signed for these data to be released.

Keywords

Prostate-specific membrane antigen (PSMA), Actinium-225, Radioligand therapy (RLT), Metastatic castration-resistant prostate cancer (mCRPC), Safety, Antitumour activity

Sustainable Development Goals

SDG-03: Good health and well-being

Citation

Sathekge, M.M., Lawal, I.O., Bal, C. et al. 2024, 'Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act) : a multicentre, retrospective study', Lancet Oncology, vol. 25, no. 2, pp. 175-183, doi : 10.1016/S1470-2045(23)00638-1.